You are here: Industry Insights > Praluent

News List

FDA approves add-on therapy for patients with genetic form of severely high cholesterol americanpharmaceuticalreview
April 07, 2021
FDA has approved Praluent (alirocumab) injection for adult patients with homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes severely high cholesterol. Praluent is not intended to be used alone but instead added to other ...
Sanofi and Regeneron to simplify antibody partnership pharmaceutical-technology
December 12, 2019
Sanofi and Regeneron Pharmaceuticals have said the companies may transform their antibody partnership, which involves Kevzara (sarilumab) and Praluent (alirocumab) drugs ...
Sanofi, Regeneron splitting up on Praluent, Kevzara fiercepharma
December 11, 2019
After more than a decade of working together, Sanofi and Regeneron's drug partnership finally turned a profit recently on the back of strong sales of blockbuster Dupixent.
EU regulators expand Praluent’s label pharmatimes
March 19, 2019
European regulators have approved a new indication for Regeneron and Sanofi’s Praluent, allowing its use to cut cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD).
Praluent (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease firstwordpharma
March 18, 2019
The European Commission (EC) has approved a new indication for Praluent®(alirocumab), to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease (ASCVD) by lowering low-density lipoprotein cholesterol (LDL-C) levels as an adj
Regeneron and Sanofi cut US list price of Praluent pharmaceutical-technology
February 13, 2019
Regeneron and Sanofi have announced they have lowered the list price of high cholesterol drug Praluent (alirocumab) in the US by approximately 60%....
Praluent not worth the price, finds study pharmaphorum
January 04, 2019
Sanofi and Regeneron’s Praluent may still not be cost effective compared to other cholesterol-lowering drugs despite a recent price cut, a new study has claimed.....
New Cholesterol Drug, Alirocumab's (Praluent), High Price May Not Be Worth It: Study drugs
January 03, 2019
Despite being slashed by half in recent months, the price tag for advanced cholesterol-fighting drugs is still too high to make them cost-effective, a new analysis has concluded.....
Amgen cuts US price of cholesterol drug by 60% pharmaphorum
December 20, 2018
Amgen is cutting the US price of its cholesterol drug Repatha by 60%, following a similar decision by rivals Sanofi and Regeneron earlier this year.
FDA to Review sBLA for Praluent americanpharmaceuticalreview
September 18, 2018
Regeneron Pharmaceuticals and Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental...

Previous page 1 2 Next page